By incorporating a gene-suppressing drug into an over-the-counter gel, researchers at Albert Einstein College of Medicine and their colleagues cut healing time by half and significantly improved healing outcomes compared to control treatments.
Results from the combination therapy, which was tested in mice, were published online today in Advances in Wound Care,
“Not only did wound healing occur more rapidly and completely, but actual regeneration occurred, with hair follicles and the skin’s supportive collagen network restored in wounded skin—clinically important improvements that are unprecedented in wound care,” says senior author David J. Sharp, Ph.D., professor of physiology & biophysics at Einstein. “We foresee this therapy having broad application for all sorts of wounds, from playground cuts to battlefield injuries to chronic wounds.”
Chronic wounds alone affect 6.5 million Americans and cost $25 billion in annual healthcare costs. Over the past several decades, few advances have been made in treating wounds of any type.
In 2015, Dr. Sharp and colleagues discovered that an enzyme called fidgetin-like 2 (FL2) puts the brakes on skin cells as they migrate towards wounds to heal them. He reasoned that reducing FL2 levels might enable healing cells to reach their destination faster. So he and his colleagues developed small interfering RNA molecules (siRNAs) that specifically inhibit the gene that codes for FL2. When the siRNAs were encased in nanoparticles and sprayed on skin wounds in mice, the treated wounds healed faster than untreated wounds.
In the current study, Dr. Sharp enhanced the siRNAs’ wound-healing potential by combining them with PluroGel—a protective gel that keeps wounds moist and has antimicrobial properties when applied to bandages and other wound dressings. In addition, Dr. Sharp incorporated the siRNAs into microparticles made of collagen, a naturally occurring protein that readily releases its siRNA “cargo” after coming in contact with the skin.
The FL2-siRNA/PluroGel combination was applied to mice with either skin excisions or burns. For comparison, studies involving both types of skin injuries also used two control groups: mice treated with PluroGel alone and mice treated with PluroGel plus siRNA that did not target the gene for FL2. Wounds were treated on the day of the skin excision or burn and again two, four and six days later. For 14 days following the injuries, wounds were assessed by investigators who were “blinded” as to the treatment the mice received.
On the fourth day after mice treated for excision wounds, the open wound areas of mice in the two control groups were nearly twice as large as the wound areas in mice treated with the FL2-siRNA/PluroGel combination. Several mice treated with the combination therapy also had hair follicles present in the wound zone, while no such structures were seen in the control mice.
For mice treated for burns: by 14-days post injury, the wounds of mice in both control groups were more than one-third larger than in the mice treated with the FL2-siRNA/PluroGel combination. In addition, the burn wounds of all mice treated with the FL2-siRNA/PluroGel combination had closed completely by day 14; by comparison, 25 percent and 30 percent of treated wounds in the PluroGel and PluroGel/nontarget siRNA control groups, respectively, remained unhealed at that time.
“These results show that FL2-siRNA plus PluroGel is a highly promising wound treatment,” says Adam Kramer, a Ph.D. candidate in Dr. Sharp’s lab and co-lead author. “By lowering FL2 levels in skin cells, the FL2-siRNA helps cells reach wound sites much faster than they ordinarily would—essential for minimizing scarring and preventing wounds from becoming chronic. And by hydrating wounds and inhibiting microbes, PluroGel offers important additional wound-healing benefits.”
Dr. Sharp and Brian O’Rourke, Ph.D., the paper’s co-lead author and chief scientist at MicroCures, Inc., have achieved similar success in treating skin wounds in pigs—animals with skin that closely resembles human skin. Dr. Sharp’s team plans to seek permission from the U.S. Food and Drug Administration to test their wound-healing therapy in clinical trials.
Learn more: Novel Combination Therapy Promotes Wound Healing
The Latest on: Combination therapy
[google_news title=”” keyword=”combination therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Combination therapy
- Novel combination therapy offers promising results for treatment-refractory hepatoblastomaon February 21, 2024 at 9:40 am
DeBakey Department of Surgery. "In this study, we investigated the potential benefits of a new combination therapy that included an inhibitor of the enzyme histone deacetylase (HDAC) present at ...
- One-Time Cell Therapy Amtagvi Gets Accelerated Approval for Advanced Melanomaon February 20, 2024 at 4:00 pm
63 received prior anti-CTLA-4 therapy, 42 received anti-PD1/anti-CTLA-4 combination therapy and 20 received a BRAF inhibitor or combination therapy with BRAF and MEK inhibitors. Among the 73 patients, ...
- FDA Approves Iovance Cancer Treatment, the First Cell Therapy for a Solid Tumoron February 20, 2024 at 6:55 am
Iovance Biotherapeutics’s Amtagvi is now the first FDA-approved treatment based on type of cell called a tumor-infiltrating lymphocyte. The regulatory nod in advanced melanoma also makes Amtagvi the ...
- Phage therapy: Researchers sharpen another arrow in the quiver against antibiotic resistanceon February 20, 2024 at 1:31 am
When growing phages, researchers need to start out with the target bacteria and infect it with the phage. The phage multiplies and blows the bacteria up. But all the bacterial debris, including the ...
- Combination Therapies Provide Optimal Hypertensive Control in Patients Taking Ibrutinibon February 17, 2024 at 5:00 am
The retrospective study found patients on Bruton’s tyrosine kinase inhibitors are similar to the general population in the sense that it usually takes at least 2 anti-hypertensive drugs to control ...
- Combination therapy shows promise in targeting latent HIV reservoirson February 14, 2024 at 4:00 pm
and other clinicians and researchers at the UNC School of Medicine suggests that a combination of the drug vorinostat and immunotherapy can coax HIV-infected cells out of latency and attack them.
- Combination Therapy in Aesthetics Market Size to Exceed US$ 8.03 Billion by 2034 with 8.1 % CAGR: Fact.MR Analysison February 13, 2024 at 5:00 am
Integration of AI and Advanced Imaging Leading to Introduction of Improved Combination Therapies in AestheticsRockville, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Fact.MR, a market research and competitive ...
- Combination therapy offers breakthrough in NSCLC treatmenton February 13, 2024 at 4:44 am
A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, ...
- Biomarker-directed combination effective in immunotherapy-resistant lung canceron February 12, 2024 at 4:00 pm
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nature Medicine , 2024; DOI: 10.1038/s41591-024-02808-y Cite This Page : ...
via Bing News